Humana slumps due to Medicaid costs

By Admin
Written by Alyssa Clark Humana is known throughout the country as one of the U.S.s leading health insurance providers, holding a firm position in the...

Written by Alyssa Clark


Humana is known throughout the country as one of the U.S.’s leading health insurance providers, holding a firm position in the insurance market for the past 10 years. This past Wednesday, representatives from Humana said they are expected a substantial decline in earnings this next year due to health exchanges and the Medicaid program which caters to the U.S.’s poor.

Underneath the national healthcare reform law, Humana and other insurance providers began administering insurance plans to people on October 1st. These state-based exchanges will become active in 2014. Humana has also overseen care contracts with a few states, in terms of managing their Medicaid health plans.

Humana projects its price per share earnings in 2014 to be around $7.25 to $7.75, which is adding in the 50-90 cents for Medicaid and health exchange costs.

"Although we expect shares to react negatively to the guidance, we find the outlook somewhat reassuring as it implies general stability in core operations/margins offset by semi-discretionary and transient upfront investment spending," Susquehanna Financial Group analyst Chris Rigg said in a research note.

In the year of 2013, Humana is still projecting earnings of $8.65 to $8.75 per share, which makes the substantial $1.40 drop stand out even more.

“Analysts on average were expecting a profit of $8.69 per share for the year”, according to Thomson Reuters I/B/E/S.

“It was not immediately clear if that consensus figure included any spending on those investments”.

Humana’s forecast for 2014 still aligns with analysts’ estimations, projecting the company to still gross $43 billion for the upcoming year.

“Third-quarter net income at Humana fell to $368 million, or $2.31 per share, from $426 million, or $2.62 per share, a year earlier. The results beat analysts' expectations of $2.15 per share. Revenue rose 7 percent to $10.32 billion from $9.65 billion a year earlier, but the company paid out more in claims and had higher operating costs”, according to Thomson Reuters.


About the Author

Alyssa Clark is the Editor of Healthcare Global


Featured Articles

WHO Health Chatbot Built on 'Humanised' GenAI

World Health Organisation's GenAI digital health tool is built using ‘AI humanisation’ tech & designed to ease burden on health workers & educate on health

Costco Weight-Loss Drugs Move Highlights US AOM Growth

Costco move to partner with online healthcare provider Sesame to provide members with weight-loss drugs including Wegovy signals US anti-obesity boom

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

As it's announced AstraZeneca's CEO Pascal Soriot's package could rise by as much as US$24mn we explore the history of the UK's most valuable business

US Academic Medical Centres 'Struggling' says McKinsey


J&J Community Initiatives Tackle US Healthcare Chasm

Medical Devices & Pharma

PitchBook: Healthcare Private Equity Deals see Decline

Health Insurance & Finance